The Present and FutureCouncil PerspectivesExercise at the Extremes: The Amount of Exercise to Reduce Cardiovascular Events
Key Words
Abbreviations and Acronyms
Cited by (0)
The views expressed in this paper by the American College of Cardiology's (ACC's) Sports and Exercise Cardiology Leadership Council do not necessarily reflect the views of the Journal of the American College of Cardiology or the ACC.
Dr. Eijsvogels is supported by a European Commission Horizon 2020 grant (Marie Sklodowska-Curie Fellowship 655502). Dr. Thompson has received research support from the National Institutes of Health, Genomas, Aventis, Roche, Sanofi, Regeneron, Esperion, Amarin and Pfizer; has served as a consultant for Amgen, AstraZeneca, Regeneron, Merck, Genomas, Abbott, Pfizer, Esperion, and Sanofi; has received speaker honoraria from Merck, AstraZeneca, Regeneron, Sanofi, and Amgen; owns stock in Abbvie, Abbott Laboratories, CVS, General Electric, Johnson & Johnson, Medtronic, and JA Wiley; and has provided expert legal testimony on exercise-related cardiac events and statin myopathy. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.